The cluster

solution was analysed using defined food grou

The cluster

solution was analysed using defined food groups in serves and with respect to clinical parameters and requirements for selected nutrients.\n\nRESULTS: buy THZ1 Two distinct dietary patterns were identified from the reported baseline dietary intakes. Subjects in Cluster 1 reported food patterns characterised by higher intakes of low-fat dairy and unsaturated oils and margarine and were generally more closely aligned to food choices encouraged in national dietary guidelines. Subjects in Cluster 2 reported a dietary pattern characterised by non-core foods and drinks, higher-and medium-fat dairy foods, fatty meats and alcohol. At 3 months, Cluster 2 subjects reported greater reductions in energy intake (-5317 kJ; P<0.001) and greater weight loss (-5.6 kg; P<0.05) compared with Cluster 1.\n\nCONCLUSIONS: Overweight subjects with reported dietary patterns similar to dietary guidelines at baseline may have more difficulty in reducing energy intake than those with poor dietary patterns. Correcting exposure to non-core foods and drinks was key to successful weight loss. European Journal of Clinical Nutrition (2013) 67, 330-336; doi:10.1038/ejcn.2013.26; published online selleck 13 February 2013″
“Background: The prevalence of obsessive-compulsive

symptoms (OCS) in patients with schizophrenia is relatively high. Antipsychotics have been found to influence OCS.\n\nObjective: To determine whether induction or severity of OCS differs during treatment with olanzapine or risperidone in young patients with early psychosis.\n\nMethods: One hundred twenty-two patients with a Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform disorder were randomized in a double-blind design to groups of 6 weeks’ treatment with olanzapine (n = 59) or Stattic datasheet risperidone (n = 63), with a mean dose of 11.3 mg olanzapine and 3.0 mg risperidone at 6 weeks. Primary outcome measures were the mean baseline-to-end point change in total score on the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS).\n\nResults:

Treatment with olanzapine was associated with greater decreases in Y-BOCS total score than treatment with risperidone in total group (N = 122: -2.2 vs -0.3, z = -2.651, P < 0.01), in patients with baseline Y-BOCS total score greater than 0 (n = 58: -5.1 vs -0.4, z = -2.717, P < 0.01), and in patients with baseline Y-BOCS total score greater than 10 (n = 29: -7.1 vs -0.6, z = -2.138, P = 0.032).\n\nConclusions: In this randomized, 6-week, double-blind trial, we found a significant and clinically relevant difference in decrease in Y-BOCS scores favoring olanzapine compared with risperidone.”
“The aim of this study was to prove the concept of using a long intravenous half-life blood-pool T1 contrast agent as a new functional imaging method.

Comments are closed.